MapLight Therapeutics Announces Updated Timing for Phase 2 Study Results
MapLight Therapeutics, Inc. (Nasdaq: MPLT) has revealed an exciting update regarding its ongoing Phase 2 clinical studies, ZEPHYR and IRIS. The San Francisco and Boston-based biopharmaceutical company anticipates that topline results for these pivotal trials will be available in the third quarter of 2026, marking a significant advancement in their research timelines.
ZEPHYR Trial Progress and Expectations
The Phase 2 ZEPHYR trial is evaluating the efficacy of ML-007C-MA for treating schizophrenia. This trial is notable for its robust enrollment, targeting 300 hospitalized adult participants who are experiencing acute exacerbations of psychosis. The study utilizes a randomized, double-blind, placebo-controlled design to ensure the validity of its results.
Chris Kroeger, co-Founder and Chief Executive Officer of MapLight, commented: “The accelerated enrollment pace in the ZEPHYR trial allows us to narrow our timing guidance to the third quarter of 2026. This momentum is testimony to our disciplined execution and commitment to advancing our programs efficiently while maintaining the highest quality standards.”
IRIS Trial Enrollment Completion
In addition to the ZEPHYR trial, MapLight has also completed enrollment for the Phase 2 IRIS trial, which investigates ML-004 for autism spectrum disorder. Like the ZEPHYR study, the IRIS trial is a double-blind, placebo-controlled experiment, successfully randomizing approximately 160 adult and adolescent participants. Topline results for this study are also expected in Q3 2026, aligning with the ZEPHYR trial's timelines.
About MapLight Therapeutics
MapLight Therapeutics is a clinical-stage biopharmaceutical company dedicated to transforming the treatment landscape for patients affected by central nervous system disorders. Founded by eminent figures in psychiatry and neuroscience, the company aims to address the lack of effective, circuit-specific pharmacotherapies by utilizing its innovative discovery platform to identify and modulate neural circuits linked to various diseases.
For more information about their initiatives and developments, visit www.maplightrx.com.
Forward-Looking Statements
This announcement includes forward-looking statements that predict future events or outcomes. Words such as “may,” “will,” “expect,” and “believe,” among others, are used to identify these forward-looking statements. While the management of MapLight believes these statements are based on reasonable estimates and assumptions, actual results could significantly differ due to various risks and uncertainties.
- Global macroeconomic conditions
- Uncertainty in clinical trial results
- Timing of regulatory approvals
- Company's operational funding capabilities
The detailed risks and uncertainties are additionally outlined in the company’s filings with the U.S. Securities and Exchange Commission (SEC).
Contact Information
For investor inquiries, please reach out to: investors@maplightrx.com
For media inquiries, contact: media@maplightrx.com